1. Home
  2. LNN vs IMTX Comparison

LNN vs IMTX Comparison

Compare LNN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lindsay Corporation

LNN

Lindsay Corporation

HOLD

Current Price

$114.59

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

IMTX

Immatics N.V.

HOLD

Current Price

$9.35

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNN
IMTX
Founded
1954
N/A
Country
United States
Germany
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
LNN
IMTX
Price
$114.59
$9.35
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$113.00
$19.00
AVG Volume (30 Days)
98.8K
539.3K
Earning Date
04-02-2026
05-13-2026
Dividend Yield
1.35%
N/A
EPS Growth
12.81
N/A
EPS
4.22
N/A
Revenue
$676,368,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.74
$25.91
P/E Ratio
$27.23
N/A
Revenue Growth
11.41
N/A
52 Week Low
$97.27
$5.29
52 Week High
$148.00
$12.41

Technical Indicators

Market Signals
Indicator
LNN
IMTX
Relative Strength Index (RSI) 49.63 49.00
Support Level $111.23 $8.56
Resistance Level $114.63 $10.55
Average True Range (ATR) 2.89 0.45
MACD -0.01 0.04
Stochastic Oscillator 41.97 55.06

Price Performance

Historical Comparison
LNN
IMTX

About LNN Lindsay Corporation

Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Share on Social Networks: